文献速递类风湿关节炎

NI-0101(抗TLR4单抗)治疗甲氨蝶呤应答不足的类风湿关节炎:II期研究

Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.
PubMed 文献 · Ann Rheum Dis · 2019-12-31

这项安慰剂对照、双盲、随机(2:1)II期研究评估了抗TLR4人源化单抗NI-0101(5 mg/kg,每2周一次,共12周)在ACPA阳性且对甲氨蝶呤应答不足的RA患者中的耐受性和疗效。90例患者随机分组(NI-0101组61例,安慰剂组29例),86例完成研究。结果显示任何疗效终点均无显著组间差异,基于基线生物标志物的亚组分析也未发现对NI-0101有应答的人群;治疗中出现的不良事件发生率安慰剂组为51.7%,NI-0101组为52.5%。

要点

  • NI-0101阻断TLR4通路在ACPA阳性MTX应答不足RA中未显示疗效。
  • 任何疗效终点均无显著组间差异,生物标志物亚组亦无应答人群。
  • 治疗中出现的不良事件发生率两组相近(51.7% vs 52.5%)。

核心结论

  • 在RA这一人类免疫介导的炎症性疾病中,首次证明单独阻断TLR4通路不能改善疾病参数。
  • 成功靶向RA固有免疫通路可能需要更广泛和/或更早期的抑制策略。

研究设计与样本

  • 安慰剂对照、双盲、随机(2:1)II期试验,评估NI-0101(5 mg/kg,每2周一次,共12周)对比安慰剂。
  • 研究对象为ACPA阳性且对甲氨蝶呤应答不足的RA患者,共90例随机(NI-0101组61例,安慰剂组29例),86例完成研究。
  • NI-0101为first-in-class人源化单抗,阻断TLR4,其作用经健康志愿者体内脂多糖诱导细胞因子释放抑制所证实。

主要发现

  • 任何疗效终点均未观察到显著组间差异。
  • 使用基线参数作为协变量的亚组分析未发现任何对NI-0101有应答的人群。
  • 治疗中出现的不良事件发生率:安慰剂组51.7%,NI-0101组52.5%。

关键数值与推荐

  • 疗效指标包括DAS28-CRP、EULAR良好与中度应答、ACR20、ACR50和ACR70应答。
  • NI-0101剂量为5 mg/kg,每2周一次,共12周。

临床怎么用

  • 结果不支持单独阻断TLR4通路用于ACPA阳性且对甲氨蝶呤应答不足的RA患者。
  • 提示未来靶向固有免疫通路可能需要更广泛和/或更早期的抑制策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-citrullinated protein antibodies (ACPAs) form immune complexes with citrullinated proteins binding toll-like receptor (TLR) 4, which has been proposed as a mediator of rheumatoid arthritis (RA). NI-0101 is a first-in-class humanised monoclonal antibody blocking TLR4, as confirmed by inhibition of in vivo lipopolysaccharide-induced cytokine release in healthy volunteers. This study was design to confirm preclinical investigations supporting a biomarker-driven approach for treatment of patients with RA who present positive for these immune complexes. METHODS: Placebo-controlled, double-blind, randomised (2:1) trial of the tolerability and efficacy of NI-0101 (5 mg/kg, every 2 weeks for 12 weeks) versus placebo in ACPA-positive RA patients with inadequate response to methotrexate. Efficacy measures included Disease Activity Score (28-joint count) with C reactive protein (DAS28-CRP), European League Against Rheumatism (EULAR) good and moderate responses, and American College of Rheumatology (ACR) 20, ACR50 and ACR70 responses. Subgroup analyses defined on biomarkers were conducted. Pharmacokinetics, pharmacodynamics and safety were reported. RESULTS: 90 patients were randomised (NI-0101 (61) and placebo (29)); 86 completed the study. No significant between-group difference was observed for any of the efficacy endpoints. Subgroup analyses using baseline parameters as covariants did not reveal any population responding to NI-0101. Treatment-emergent adverse events occurred in 51.7% of patients who received placebo versus 52.5% for NI-0101. CONCLUSIONS: We demonstrate for the first time that in RA, a human immune-mediated inflammatory disease, blocking the TLR4 pathway alone does not improve disease parameters. Successful targeting of innate immune pathways in RA may require broader and/or earlier inhibitory approaches.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Monnet E, Choy EH, McInnes I, et al. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Ann Rheum Dis. 2019. PMID: 31892533. doi:10.1136/annrheumdis-2019-216487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。